PL366899A1 - An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases - Google Patents

An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Info

Publication number: PL366899A1
Authority: PL; Poland
Prior art keywords: adenosine; combination; receptor agonist; anticholinergic agent; obstructive airways
Prior art date: 2001-05-25

Application number

PL02366899A

Other languages

Polish (pl)

Inventor

Michael Yeadon

Roisin A. Armstrong

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-25

Filing date

2002-05-24

Publication date

2005-02-07

2001-12-06 Priority claimed from GB0129275A external-priority patent/GB0129275D0/en

2002-05-03 Priority claimed from GB0210238A external-priority patent/GB0210238D0/en

2002-05-24 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2005-02-07 Publication of PL366899A1 publication Critical patent/PL366899A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL02366899A 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases PL366899A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29384201P	2001-05-25	2001-05-25
GB0129275A GB0129275D0 (en)	2001-12-06	2001-12-06	Pharmaceutical combination
GB0210238A GB0210238D0 (en)	2002-05-03	2002-05-03	Pharmaceutical composition

Publications (1)

Publication Number	Publication Date
PL366899A1 true PL366899A1 (en)	2005-02-07

Family

ID=27256345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02366899A PL366899A1 (en)	2001-05-25	2002-05-24	An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Country Status (22)

Country	Link
US (1)	US20040171576A1 (en)
EP (1)	EP1395287A1 (en)
KR (1)	KR20030097901A (en)
CN (1)	CN1535161A (en)
AP (1)	AP2003002911A0 (en)
BG (1)	BG108383A (en)
BR (1)	BR0209986A (en)
CA (1)	CA2448086A1 (en)
CO (1)	CO5540324A2 (en)
CZ (1)	CZ20033126A3 (en)
EE (1)	EE200300586A (en)
HU (1)	HUP0400029A2 (en)
IL (1)	IL158774A0 (en)
MA (1)	MA27028A1 (en)
MX (1)	MXPA03010787A (en)
NO (1)	NO20035202D0 (en)
OA (1)	OA12609A (en)
PA (1)	PA8546101A1 (en)
PL (1)	PL366899A1 (en)
SK (1)	SK14302003A3 (en)
SV (1)	SV2003001055A (en)
WO (1)	WO2002096462A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7378400B2 (en)	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en)	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
NZ532062A (en)	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GB0129273D0 (en)	2001-12-06	2002-01-23	Pfizer Ltd	Crystalline drug form
AR044519A1 (en)	2003-05-02	2005-09-14	Novartis Ag	DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
PE20060272A1 (en)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
WO2006028618A1 (en)	2004-08-02	2006-03-16	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
SG155182A1 (en)	2004-08-02	2009-09-30	Univ Virginia	2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006023272A1 (en)	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0511065D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
MX2009003185A (en)	2006-09-29	2009-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors.
AU2007315234A1 (en)	2006-10-30	2008-05-08	Novartis Ag	Heterocyclic compounds as antiinflammatory agents
CN101910153B (en)	2008-01-11	2014-01-22	诺华股份有限公司	Pyrimidines as Kinase Inhibitors
PT2391366E (en)	2009-01-29	2013-02-05	Novartis Ag	Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en)	2009-08-12	2016-05-17	Novartis Ag	Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
PE20121148A1 (en)	2009-08-17	2012-09-07	Intellikine Llc	HETEROCYCLIC COMPOUNDS AND USES OF THEM
BR112012008061A2 (en)	2009-08-20	2016-03-01	Novartis Ag	heterocyclic oxime compounds
UY33597A (en)	2010-09-09	2012-04-30	Irm Llc	COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (en)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	Heterocyclic compounds and uses thereof
BR112013021638A2 (en)	2011-02-25	2016-08-02	Irm Llc	"trk inhibiting compounds, their use and compositions comprising them"
EP2755976B1 (en)	2011-09-15	2018-07-18	Novartis AG	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
JP2015512425A (en)	2012-04-03	2015-04-27	ノバルティスアーゲー	Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
TW202140550A (en)	2020-01-29	2021-11-01	瑞士商諾華公司	Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU5879299A (en) *	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
GB9924363D0 (en) *	1999-10-14	1999-12-15	Pfizer Central Res	Purine derivatives

2002
- 2002-05-24 BR BR0209986-1A patent/BR0209986A/en not_active IP Right Cessation
- 2002-05-24 AP APAP/P/2003/002911A patent/AP2003002911A0/en unknown
- 2002-05-24 CZ CZ20033126A patent/CZ20033126A3/en unknown
- 2002-05-24 EE EEP200300586A patent/EE200300586A/en unknown
- 2002-05-24 WO PCT/EP2002/005725 patent/WO2002096462A1/en not_active Ceased
- 2002-05-24 HU HU0400029A patent/HUP0400029A2/en unknown
- 2002-05-24 CN CNA028106180A patent/CN1535161A/en active Pending
- 2002-05-24 PL PL02366899A patent/PL366899A1/en unknown
- 2002-05-24 MX MXPA03010787A patent/MXPA03010787A/en unknown
- 2002-05-24 IL IL15877402A patent/IL158774A0/en unknown
- 2002-05-24 KR KR10-2003-7015411A patent/KR20030097901A/en not_active Ceased
- 2002-05-24 SV SV2002001055A patent/SV2003001055A/en not_active Application Discontinuation
- 2002-05-24 CA CA002448086A patent/CA2448086A1/en not_active Abandoned
- 2002-05-24 US US10/479,085 patent/US20040171576A1/en not_active Abandoned
- 2002-05-24 EP EP02745316A patent/EP1395287A1/en not_active Withdrawn
- 2002-05-24 OA OA1200300303A patent/OA12609A/en unknown
- 2002-05-24 PA PA20028546101A patent/PA8546101A1/en unknown
- 2002-05-24 SK SK1430-2003A patent/SK14302003A3/en not_active Application Discontinuation
2003
- 2003-11-18 CO CO03101662A patent/CO5540324A2/en not_active Application Discontinuation
- 2003-11-20 MA MA27409A patent/MA27028A1/en unknown
- 2003-11-24 NO NO20035202A patent/NO20035202D0/en not_active Application Discontinuation
- 2003-11-24 BG BG108383A patent/BG108383A/en unknown

Also Published As

Publication number	Publication date
IL158774A0 (en)	2004-05-12
US20040171576A1 (en)	2004-09-02
KR20030097901A (en)	2003-12-31
AP2003002911A0 (en)	2003-12-31
CA2448086A1 (en)	2002-12-05
MXPA03010787A (en)	2004-03-02
CN1535161A (en)	2004-10-06
BR0209986A (en)	2004-04-06
SK14302003A3 (en)	2004-08-03
EE200300586A (en)	2004-04-15
OA12609A (en)	2006-06-09
NO20035202D0 (en)	2003-11-24
MA27028A1 (en)	2004-12-20
BG108383A (en)	2004-08-31
SV2003001055A (en)	2003-11-14
WO2002096462A1 (en)	2002-12-05
EP1395287A1 (en)	2004-03-10
PA8546101A1 (en)	2003-12-10
CO5540324A2 (en)	2005-07-29
CZ20033126A3 (en)	2004-09-15
HUP0400029A2 (en)	2004-04-28

Publication	Publication Date	Title
IL158774A0 (en)	2004-05-12	An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
AU2003273300A8 (en)	2004-03-29	Modified glp-1 receptor agonists and their pharmacological methods of use
HUP0401191A3 (en)	2006-11-28	Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
IL130424A (en)	2003-10-31	Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
GB0111872D0 (en)	2001-07-04	Therapeutic agents and methods
HUE039348T2 (en)	2018-12-28	A2A receptor antagonists for use in the treatment of movement disorders
AU2002314110A1 (en)	2002-12-03	Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
IL158776A0 (en)	2004-05-12	A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200503645B (en)	2006-11-29	Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
AU6808901A (en)	2001-12-11	Adenosine a2a receptor antagonists
IL152531A0 (en)	2003-05-29	Tropane derivatives useful in therapy
IL211288A0 (en)	2011-04-28	Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
AU2002351397A8 (en)	2003-07-09	Systems and methods using vasoconstriction for improved thermal treatment of tissues
IL142132A0 (en)	2002-03-10	Methods and compositions for treating receptor mediated diseases
IL160706A0 (en)	2004-08-31	Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use
PL377791A1 (en)	2006-02-20	3-amino-piperidine derivatives and processes for their preparation
IL161572A0 (en)	2004-09-27	Adenosine a2a receptor antagonists
AP2004003147A0 (en)	2004-09-30	Tropane derivatives useful in therapy
IL149495A0 (en)	2004-03-28	Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
AU5977501A (en)	2001-11-26	Method for treating retinal degeneration with purinergic receptor agonists
AU2003247834A8 (en)	2004-01-19	Therapeutic agent delivery device and method
ZA200308465B (en)	2004-11-01	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
IL156647A0 (en)	2004-01-04	2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
PL363048A1 (en)	2004-11-15	Azabicyclic derivatives and their therapeutic use
MXPA03001609A (en)	2003-06-04	Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors.